Literature DB >> 9292671

Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.

A Wedrich1, R Menapace, E Ries, I Polzer.   

Abstract

PURPOSE: To evaluate the efficacy and complications of intracameral recombinant tissue plasminogen activator (r-tPA) in the treatment of severe fibrinous effusion after cataract and combined cataract and glaucoma surgery.
SETTING: University Eye Hospital Vienna, Austria.
METHODS: In a prospective study, 40 eyes of 39 patients with severe fibrinous anterior chamber reaction in the early postoperative course received 25 microg r-tPA intracamerally through a temporal paracentesis. The main outcome measures were rate of complete fibrinolysis, time of maximal effect, and complications.
RESULTS: Complete fibrinolysis occurred in 33 eyes (83%) after a mean of 3.2 hours +/- 0.9 (SD). The rate of complete fibrinolysis was higher in eyes having cataract surgery only (24 eyes, 89%) than in those having combined surgery (9 eyes, 69%). Recurrent fibrin was seen in 3 eyes (7%), small anterior chamber hemorrhage in 7 (18%), increased intraocular pressure in 3 (7%), and posterior synechias in 13 (33%). Complications were managed conservatively.
CONCLUSION: The intracameral injection of 25 microg r-tPA proved to be a safe, efficient, and low-risk supplement in the treatment of severe postoperative fibrinous reactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292671     DOI: 10.1016/s0886-3350(97)80246-5

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  9 in total

1.  Tissue plasminogen activator therapy for the eye.

Authors:  R C Tripathi; B J Tripathi
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

2.  Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

Authors:  Rosana Gerometta; Sandeep Kumar; Shaily Shah; Larry Alvarez; Oscar Candia; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-03       Impact factor: 4.799

3.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

4.  Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.

Authors:  H Siatiri; A H Beheshtnezhad; H Asghari; N Siatiri; S Moghimi; N Piri
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

5.  Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep.

Authors:  Oscar A Candia; Rosana M Gerometta; John Danias
Journal:  Exp Eye Res       Date:  2014-10-07       Impact factor: 3.467

6.  Retinal toxicity of intravitreal tenecteplase in the rabbit.

Authors:  S A Rowley; S Vijayasekaran; P K Yu; I L McAllister; D-Yi Yu
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

7.  Intracameral recombinant tissue plasminogen activator for refractory glaucoma secondary to a fungal corneal abscess.

Authors:  L Jay Katz; Oana Stirbu; Garth Willis; Parul Ichhpujani
Journal:  Open Ophthalmol J       Date:  2009-09-25

8.  Successful pediatric DMEK facilitated by intracameral tissue plasminogen activator to mitigate anterior chamber fibrin reaction.

Authors:  Tanner J Ferguson; Elias I Traboulsi; Jeffrey M Goshe
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-30

9.  Intraoperative fibrin formation during Descemet membrane endothelial keratoplasty.

Authors:  Matthew Benage; Michael Korchak; Michelle Boyce; Zachary M Mayko; Alex Bauer; Michael D Straiko; Mark A Terry; Christopher S Sáles; Mark A Greiner
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.